Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications
Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications
复制标题
DOI：
10.3945/ajcn.2008.26561
复制
发表时间：
2009-01-01
影响因子：
7.1
通讯作者：
Takahashi, Michio
中科院分区：
文献类型：
--
作者：
Snitker, Soren;Fujishima, Yoshiyuki;Takahashi, Michio
背景资料：辣椒酯类化合物是一种非刺激性的辣椒素相关物质，对动物的代谢和体重有影响。目的：我们的目的是探索口服辣椒酯类化合物（6 mg/d）对减肥、减脂和代谢变化的安全性和有效性，并检查候选基因是否是辣椒酯类化合物反应的预测因子。设计：这是一项为期12周、安慰剂对照、双盲、随机化研究。合格标准包括体重指数（BMI;以kg/m2计）为25-35。测量体重，双能X线吸收法，间接热量测定法（男性），和基因分型carried.Results：40名妇女和40名男子的平均（+/- SD）年龄为42 +/- 8岁和BMI为30.4 +/- 2.4被随机分配到辣椒素或安慰剂组。辣椒酯类耐受性良好。辣椒酯类物质组和安慰剂组的平均（+/- SD）体重变化分别为0.9 +/- 3.1和0.5 +/- 2.4 kg（P = 0.86）。在肥胖的总体变化方面没有显著的组间差异，但是辣椒酯类物质组的腹部肥胖减少（-1.11 +/-1.83%）比安慰剂组（-0.18 +/-1.94%）更多（P = 0.049），并且这种变化与体重的变化相关（r = 0.46，P < 0.0001）。静息能量消耗的变化在组间没有显著差异，但辣椒碱组在研究结束时的脂肪氧化较高（最小二乘平均差异：21.0 mg/min; P = 0.06）。13个基因变异测试，TRPV 1 Val 585 Ile和UCP 2 - 866 G/A相关的腹部adiposity.Conclusions的变化显着：治疗与6毫克/天辣椒酯类口服似乎是安全的，并与腹部脂肪损失。辣椒酯类物质的摄入与脂肪氧化的增加几乎是显着的。我们确定了2种常见的遗传变异，可能是治疗反应的预测因子。美国临床营养杂志2009; 89：45-50。
Background: Capsinoids from the Capsicum genus of plants are nonpungent capsaicin-related substances with effects on metabolism and body weight in animals.Objectives: Our objectives were to explore the safety and efficacy of capsinoids taken orally (6 mg/d) for weight loss, fat loss, and change in metabolism and to examine whether candidate genes are predictors of capsinoid response.Design: This was a 12-wk, placebo-controlled, double-blind, randomized study. Eligibility criteria included a body mass index (BMI; in kg/m(2)) of 25-35. Body weight was measured, and dualenergy X-ray absorptiometry, indirect calorimetry (men only), and genotyping were conducted.Results: Forty women and 40 men with a mean (+/- SD) age of 42 +/- 8 y and BMI of 30.4 +/- 2.4 were randomly assigned to a capsinoid or placebo group. Capsinoids were well tolerated. Mean (+/- SD) weight change was 0.9 +/- 3.1 and 0.5 +/- 2.4 kg in the capsinoid and placebo groups, respectively (P = 0.86). There was no significant group difference in total change in adiposity, but abdominal adiposity decreased more (P = 0.049) in the capsinoid group (-1.11 +/- 1.83%) than in the placebo group (-0.18 +/- 1.94%), and this change correlated with the change in body weight (r = 0.46, P, < 0.0001). Changes in resting energy expenditure did not differ significantly between groups, but fat oxidation was higher at the end of the study in the capsinoid group (least-squares mean difference: 21.0 mg/min; P = 0.06). Of 13 genetic variants tested, TRPV1 Val585Ile and UCP2 -866 G/A correlated significantly with change in abdominal adiposity.Conclusions: Treatment with 6 mg/d capsinoids orally appeared to be safe and was associated with abdominal fat loss. Capsinoid ingestion was associated with an increase in fat oxidation that was nearly significant. We identified 2 common genetic variants that may be predictors of therapeutic response. Am J Clin Nutr 2009; 89: 45-50.